NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Stock Information for BIMI International Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BIMI International Medical Inc.

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
NuCana Compliant with All Nasdaq Continued Listing Criteria
NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
NuCana Announces ADS Ratio Change

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.